Humanized CAR-T-mesothelin
Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
|
Principal Investigator |
Phase | Penn Study Number | Clinicaltrials.gov ID |
|---|---|---|---|
| Janos Tanyi, MD PhD | 1 | UPCC02916 | NCT03054298 |
Purpose
Phase I study to establish safety and feasibility of intravenous or intrapleural administered lentiviral transduced huCART-meso cells with or without lymphodepletion. Intravenous administration of huCART-meso cells is planned with or without cyclophosphamide as lymphodepleting chemotherapy.
Check Eligibility For This Trial
To inquire about participating in this study, please contact Kim Shea, RN at 215-222-2222 or Email